Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth, Progenics To Develop Methylnaltrexone Franchise

This article was originally published in The Pink Sheet Daily

Executive Summary

Companies plan to file NDAs for three formulations of the bowel dysfunction treatment over the next few years.

You may also be interested in...



Wyeth/Progenics Oral Methylnaltrexone Pushed Back A Year To Test New Formula

Companies expect to submit an NDA for the oral formulation to treat opioid-induced constipation in 2009/2010 after initiating a new Phase II trial.

Wyeth/Progenics Oral Methylnaltrexone Pushed Back A Year To Test New Formula

Companies expect to submit an NDA for the oral formulation to treat opioid-induced constipation in 2009/2010 after initiating a new Phase II trial.

Majority Of Wyeth Growth Pegged To Licensed Biotech Products, Execs Say

Half of big pharma’s developmental pipeline should come from outside innovators, Wyeth BioPharma’s Redmund says.

Related Content

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel